Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer” - Chenglong Wang; Shuai An; Fang-Tong Liu (Journal for ImmunoTherapy of Cancer)